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BACKGROUND: Cancer cells are highly dependent on glycolysis. Our aim was to determine if switching metabolism from glycolysis
towards mitochondrial respiration would reduce growth preferentially in colorectal cancer cells over normal cells, and to examine the
underlying mechanisms.
METHODS: Representative colorectal cancer and non-cancerous cell lines were treated with dichloroacetate (DCA), an inhibitor of
pyruvate dehydrogenase kinase.
RESULTS: Dichloroacetate (20mM) did not reduce growth of non-cancerous cells but caused significant decrease in cancer cell
proliferation (P¼0.009), which was associated with apoptosis and G2 phase cell-cycle arrest. The largest apoptotic effect was evident
in metastatic LoVo cells, in which DCA induced up to a ten-fold increase in apoptotic cell counts after 48h. The most striking G2
arrest was evident in well-differentiated HT29 cells, in which DCA caused an eight-fold increase in cells in G2 phase after 48h.
Dichloroacetate reduced lactate levels in growth media and induced dephosphorylation of E1a subunit of pyruvate dehydrogenase
complex in all cell lines, but the intrinsic mitochondrial membrane potential was reduced in only cancer cells (P¼0.04).
CONCLUSIONS: Pyruvate dehydrogenase kinase inhibition attenuates glycolysis and facilitates mitochondrial oxidative phosphorylation,
leading to reduced growth of colorectal cancer cells but not of non-cancerous cells.
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Colorectal cancer is the third most common cancer in the
world and the fourth leading cause of cancer-related death
(Shike et al, 1990). In 2007 colorectal cancer accounted for 17.1
deaths per 100000 persons in the United Kingdom (UK Bowel
Cancer Statistics, 2009). Despite recent advances, the prognosis of
patients with advanced and metastatic colorectal cancer remains
poor. Targeting tumour metabolism for cancer therapy is a rapidly
developing area (Pan and Mak, 2007). Early observations
concerning the metabolic differences between cancer and normal
cells were made by Otto Warburg, who showed that cancer cells are
inherently dependent on glycolysis for production of chemical
energy (Warburg, 1956). There is now mounting evidence that this
increased glycolysis results from the influence of multiple
molecular pathways, including adaptive responses to the hypoxic
tumour microenvironment, oncogenic signalling, and mito-
chondrial dysfunction (Gatenby and Gillies, 2004; Gillies and
Gatenby, 2007; Wu et al, 2007). The glycolytic phenotype offers
growth advantages to cancer cells by resisting apoptosis, and
facilitating tumour spread and metastasis (Yeluri et al, 2009).
A key regulator of cellular metabolism is pyruvate dehydro-
genase (PDH). Pyruvate dehydrogenase converts pyruvate,
produced from glycolysis, to acetyl-CoA, which is oxidised in the
tricarboxylic acid cycle within mitochondria. Pyruvate dehydro-
genase activity is tightly regulated by inhibitory phosphorylation
by pyruvate dehydrogenase kinase (PDK). Phosphorylation occurs




300 (Rardin et al, 2009). Dichloroacetate (DCA) is an
inhibitor of all the four isoenzymes of PDK(1–4) (Stacpoole,
1989), and has recently been shown to reduce growth of lung,
endometrial, and breast cancer cell lines (Bonnet et al, 2007; Wong
et al, 2008; Sun et al, 2009). It has been reported to reduce growth
of these cancer cells mainly by reducing inhibitory phosphory-
lation of PDH, thereby promoting mitochondrial oxidative
phosphorylation and inducing apoptosis through mitochondrial,
NFAT-Kv 1.5, and p53 upregulated modulator of apoptosis
(PUMA)-mediated pathways.
Colorectal cancer cells have been found to undergo increased
glycolysis (Bi et al, 2006), and the tumour microenvironment has
been found to be hypoxic and acidotic, mainly due to poorly
developed blood supply (Dewhirst et al, 1989; Milosevic et al,
2004). We have previously shown that this is especially true for
the more aggressive phenotype (Thorn et al, 2009), and expression
of the important markers of hypoxia is increased in colorectal
cancer especially at the invasive margin (Rajaganeshan et al, 2008,
2009). The purpose of this study was to investigate the effects of
DCA on the growth of colorectal cancer cells in an attempt to
examine PDK inhibition as a novel therapeutic strategy against
colorectal cancer.
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All cell lines were purchased from American Type Culture Collection
(Manassas, VA, USA) or European Collection of Cell Cultures
( S a l i s b u r y ,W i l t s h i r e ,U K ) :H B 2( b reast epithelial cells of non-cancer
origin), 293 (epithelial cells from human embryo kidney), HT29 (well-
differentiated primary colorectal adenocarcinoma), SW480 (poorly
differentiated primary colorectal adenocarcinoma), and LoVo (meta-
static left supraclavicular lymph node from colorectal adenocarcinoma).
2 9 3a n dH B 2c e l l sw e r em a i n t a i n e di nD M E Mm e d i u m ,H T 2 9a n d
SW480 in RPMI 1640 medium, and LoVo in F12 medium (all from
I n v i t r o g e n ,C a r l s b a d ,C A ,U S A ) ,supplemented with 10% fetal calf
serum, in a 371C, 5% CO2 humidified incubator. For experiments under
hypoxic conditions, we incubated cells in a humidified, hypoxic
incubator (1% O2,5 %C O 2, 94% N2,3 7 1C). Sodium dichloroacetate
(Specials Lab, Prudhoe, UK) was donated by the Pharmacy Department
at St. James’s University Hospital, Leeds, UK.
MTT assays
Cells (1 10
4) per well were seeded in 96-well tissue culture plates.
After overnight incubation, we replaced media with fresh media
containing increasing doses of DCA (0, 10, 15, 20, 30, 50, and
100mM). After 24 and 48h of incubation, we performed MTT assay
by replacing the media with 50ml of 1mgml
 1 MTT solution and
the plates were incubated in the dark for 3h. MTT solution was
then removed and the dark blue formazan precipitates were
dissolved in 100ml of propan-1-ol. Optical density was measured
using microplate reader (Opsys MR; Dynex Technologies Ltd,
Worthing, West Sussex, UK) at 570nm.
Annexin V and 7-AAD assays
Cells were seeded in 25cm
2 tissue culture flasks and incubated
overnight in standard conditions. Media was replaced with fresh
media containing a range of doses of DCA (0, 10, 20, and 50mM).
Flow cytometric analysis was performed after 24 and 48h of incu-
bation. Cells were washed twice with cold PBS and resuspended in
1  binding buffer (BD Bioscience, Franklin Lakes, NJ, USA) at
5 10
6 cells per ml. 100mlo fs o l u t i o n( 5 10
5 cells) was transferred to
5m lc u l t u r et u b e s .T h e s ec e l l sw e r es t a i n e dw i t h5ml annexin V-FITC
and 10ml 7-AAD (BD Bioscience), gently vortexed, and incubated at
ambient temperature for 15min in dark. Following this 400ml1  
binding buffer was added to each tube and analysed within an hour on
LSR II flow cytometer (BD Bioscience).
Propidium iodide assays
Cells were propagated as mentioned for the apoptosis assay.
Dichloroacetate (50mM) was used and compared to vehicle control.
After harvesting, we resuspended cells in 350ml of PBS at a
concentration of 0.5–1.0 10
6 cells per ml. 100ml of 0.25mgml
 1
propidium iodide (PI)/5% Triton (Sigma, St Louis, MO, USA) was
added to the cell suspension. 50ml of 1mgml
 1 ribonuclease A
(Sigma) was then added. Sample tubes were thoroughly vortexed and
incubated for 10min in the dark at room temperature. Flow cytometry
was performed on LSR II flow cytometer (BD Bioscience) and data
were analysed using FlowJo software (FlowJo, Ashland, OR, USA).
Lactate measurements
Lactate measurements in growth media were performed by the
chemical pathology department at the General Infirmary, Leeds
Teaching Hospitals NHS Trust. Cells were incubated in 25cm
2
flasks overnight in normoxia. Media was replaced next day with a
range of doses of DCA (0, 10, 20, and 50mM). After 48h of incu-
bation, we collected 2ml of media in fluoride tubes and transferred
immediately to the chemical pathology laboratory. The tubes
were maintained on ice during the transfer. Lactate levels were
measured using an automated analyser (Advia 1200 Chemistry
system; Siemens Healthcare Diagnostics, Camberley, Surrey, UK).
TMRM assays
Cells were treated with DCA as described for the apoptosis assay.
After 24 and 48h of incubation, we washed cells in PBS, and
suspended 1 10
6 cells per ml in Hank’s buffered salt solution with
50nM tetramethylrhodamine methyl ester (TMRM) (Invitrogen).
100ml of the cell suspension (1 10
5 cells per well) was transferred
to opaque 96-well plates, incubated for 30min, and fluorescence was
measured at 530/620nm at 371C using a plate reader (Mithras LB 40;
Berthold Technologies, Bad, Wildbad, Germany).
Western blotting
Cells were treated with DCA as described above. After 8h of
treatment, we extracted proteins from cells in Laemmli buffer (2%
SDS, 10% glycerol, 0.7% 2-mercaptoethanol, 0.05% bromophenol
blue, and 0.5 M Tris-HCl). Lysates were resolved by electrophoresis
on NuPAGE Novex 12% Bis-Tris gels (Invitrogen) in MOPS-SDS
running buffer (Invitrogen). Proteins were transferred to a poly-
vinylidene fluoride membrane (GE Healthcare, Chalford St Giles,
Bucks, UK). The membrane was blocked for 1h at ambient
temperature in 5% skimmed milk in TBS-T (Tris-buffered saline
with 0.1% Tween). The membrane was then probed with primary
antibodies in 1% skimmed milk in TBS-T for 90min, washed in
TBS-T, and then probed with the appropriate horseradish per-
oxidase (HRP)-conjugated secondary antibody for 60min. Primary
antibodies rabbit polyclonal phosphodetect anti-PDH-E1a (pSer
293),
1:500 (AP1062; EMD Chemicals, Darmstadt, Germany), and mouse
monoclonal anti-PDHE1a, 1:500 (459400; Invitrogen). Secondary
antibodies anti-rabbit or anti-mouse HRP conjugates, 1:1000 (Dako,
Glostrup, Denmark). Proteins were visualised with Supersignal West
Pico or Femto chemiluminescent substrate (Pierce Biotechnology,
Rockford, IL, USA) and the Chemidoc XRS system (Bio-Rad,
Hercules, CA, USA). b-Actin was used as a loading control.
Statistical analyses
Flow cytometry data were acquired using specific software, BD
FACSDiva 6.0 and FlowJo software. Statistical analyses were
performed using SPSS for Windows (SPSS version 15.0, Chicago,
IL, USA). Differences between DCA-treated and vehicle control
groups were assessed using the Mann–Whitney U-test and the
95% confidence intervals of the difference in means between
the two groups. A P-value of less than 0.05 was considered to be
statistically significant. Data are represented as mean from at least
three independent experiments and error bars represent standard
deviation of mean.
RESULTS
DCA reduces cancer cell proliferation and the effect is
similar in normoxia and hypoxia
First, we wished to determine if treatment with DCA inhibited
cellular proliferation and whether there would be a differential
response in cancer and non-cancerous cells in normoxic and
hypoxic conditions. With respect to hypoxia, our hypothesis was
that influence of DCA would be particularly potent with oxygen
levels that are insufficient to support additional oxidative
phosphorylation. All cell lines (HB2, 293, HT29, SW480, and
LoVo) were treated with a range of doses of DCA for 24–48h in
normoxic and hypoxic conditions. Relative cell numbers were
assessed using MTT assays.
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sTreatment with increasing doses of DCA reduced cellular
proliferation in a dose-dependent manner (Figure 1A-D). Contrary
to our expectation, the profiles of reduced cell growth were similar
in hypoxia and normoxia. At 24 and 48h, up to 20mM DCA did not
affect the growth of cultures of the non-cancerous cells, HB2 and
293. However, 20mM DCA significantly reduced growth of cultures
of all three colorectal cancer cell lines (Pp0.009). The effect of
DCA was greater on the poorly differentiated SW480 cells and the
metastatic LoVo cells than the well-differentiated HT29 cells. The
growth of cultures of LoVo cells treated with 20mM DCA was
reduced by up to 40% compared to cells treated with vehicle control.
Because there was relatively little difference in the reduction of
growth of cultures treated with DCA in hypoxic and normoxic
conditions, further experiments were performed only in normoxia.
DCA promotes apoptosis in cancer cells sparing
non-cancerous cells
Next, we wished to investigate whether the reduced growth of
cultures on treatment with DCA was associated with induction of
apoptosis. Cells were treated with range of doses of DCA (0, 10, 20,
and 50mM) for 24 and 48h, and the proportion of cells undergoing
apoptosis was assessed by detecting membrane phosphatidylserine
with annexin V-FITC. Cells were stained with annexin V-FITC and
vital dye 7-AAD, and analysed using flow cytometry. There was a
dose-dependent induction of apoptosis in the cancer cell lines after
24 and 48h of treatment, with little, if any, apoptosis induced in
the non-cancerous cells (Figure 2A and B). The greatest effect
was observed in the metastatic LoVo cells; 50mM DCA caused a
ten-fold increase in the proportion of apoptotic cells after 48h,
whereas there was a seven- and five-fold increase in HT29 and
SW480 cells, respectively. Increase in the mean percentage of total
apoptotic cells with 50mM DCA was: 2.8 (95% CI: 2–3) in HT29
cells, 3.5 (95% CI: 2–5) in SW480 cells, and 21 (95% CI: 8–34) in








































































Hypoxia 48 h Normoxia 48 h
Hypoxia 24 h Normoxia 24 h
HB2 LoVo SW480 HT29 293
HB2 LoVo SW480 HT29 293 HB2 LoVo SW480 HT29 293
HB2 LoVo SW480 HT29 293
Figure 1 Dichloroacetate (20mM) did not significantly reduce growth of cultures of the non-cancerous 293 and HB2 cells but caused a significant
reduction in growth of cultures of all the colorectal cancer cells (*Pp0.009). Cells were treated with various doses of DCA or vehicle control in normoxia
(A and C) or hypoxia (B and D), and the relative number of viable cells was assessed at 24h (A and B) and 48h (C and D) using MTT assay. Data are



































































HB2 LoVo SW480 HT29 293
HB2 LoVo SW480 HT29 293
Figure 2 Dichloroacetate induced a dose-dependent increase in
percentage of the apoptotic population in the cancer cells with minimal
apoptosis in the non-cancerous cells. Cells were treated with doses of
DCA for 24h (A) and 48h (B), stained with annexin V-FITC and 7-AAD,
and analysed with flow cytometry. Data points represent the mean (±s.d.)
of three independent experiments for 0 and 50mM DCA (* – significant
difference relative to control).
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seven with 50mM DCA, 0.2 (95% CI:  0.2 to 0.6). In HB2 cells, there
was a nonsignificant decrease in the percentage of apoptotic cells
on treatment with 50mM DCA,  0.9 (95% CI:  2.2 to 0.4).
DCA induces G2 phase arrest in colorectal cancer cells
but has no effect on cell-cycle profile of non-cancerous
293 cells
We also wished to examine whether the reduction in growth of
cultures on treatment with DCA was associated with induction of
growth arrest. Cells were treated with 50mM DCA for 24 or 48h,
and cell-cycle profiles were analysed using flow cytometric
assessment of DNA content after PI staining. Dichloroacetate
treatment caused changes in the cell-cycle profiles of all the cancer
cells but did not affect the non-cancerous cells. The changes in
cell-cycle profile were detectable after 24h of treatment, and were
persistent at 48h (Figure 3A and B).
After 48h of treatment with 50mM DCA, there was an eight-fold
increase in the cells in G2 phase in HT29 and SW480 cells, and
three-fold increase in LoVo cells. Increase in the mean percentage
of all cancer cells in G2 phase was: 21 (95% CI: 13–30) for HT29, 19
(95% CI: 13–24) for SW480 cells, and 14 (95% CI: 10–21) for LoVo
cells; whereas there was no difference in the 293 cells, 1 (95% CI:
 4 to 7), and HB2 cells,  0.3 (95% CI:  9 to 9). There was a
corresponding decrease in cells in G0/G1 phase in all cancer cell
lines. Intriguingly, in HT29 cells there was a small decrease, but in
SW480 and LoVo cells there was a significant increase in the
proportion of cells considered to be in the S phase (see Discussion
section). The cell-cycle profile of 293 and HB2 cells changed
minimally on treatment with DCA.
DCA reduces extracellular lactate levels in growth media
To establish whether the changes in growth and apoptosis induced
by DCA correlated with reduced glycolysis, we measured lactate
levels in growth media. Lactic acid is the end product of glycolysis.
If DCA were inducing mitochondrial oxidative phosphorylation,
pyruvate would be decarboxylated to acetyl-CoA and not reduced
to lactate, hence lactate levels in the growth media would decrease.
Lactate levels in growth media of all cell lines were measured after
48h of treatment with a range of doses of DCA (Figure 4). Lactate
levels were determined with an auto-analyser that is used routinely
for biochemical measurement of lactate levels; the assays are based
on a colorimetric reaction catalysed by lactate oxidase. Treatment
with DCA reduced extracellular lactate levels in growth media in
a dose-dependent manner in all the cancer and non-cancerous
cell lines.
DCA depolarises the intrinsic mitochondrial membrane in
colorectal cancer cells but not in non-cancerous cells
To verify if the induction of apoptosis in cancer cells on treatment
with DCA was associated with promotion of mitochondrial
oxidative phosphorylation, we measured the intrinsic mitochon-
drial membrane potential (DCm). Escalation of mitochondrial
respiration would reactivate the electron transport chain and
reduce the hyperpolarised DCm in cancer cells. Cells were treated
with doses of DCA for 24 and 48h and stained with the dye TMRM,
which allows fluorescent measurement of DCm.
As with previous experiments, the effect of DCA was apparent
after 24h of treatment and persisted at 48h (Figure 5A and B).
Dichloroacetate treatment reduced the hyperpolarised DCm in all
the cancer cells in a dose-dependent manner. Dichloroacetate did
not have any effect on DCm of the non-cancerous HB2 cells,
whereas, surprisingly the DCm of the non-cancerous 293 cells
increased in a dose-dependent manner. At 24h of treatment,
50mM DCA significantly reduced DCm in all cancer cells; however,
in LoVo cells there was a significant reduction even with 20mM
DCA (Figure 5A, P¼0.02). In the non-cancerous 293 cells, there
was a trend towards increase in DCm on DCA treatment, although
this was not statistically significant (P¼0.08). At 48h of treatment,
there was significant reduction of DCm in all cancer cells and










































DCA – + – + – + – + – +
HB2 293 HT29 SW480 LoVo
DCA − + − + − + − + − +
293 HT29 SW480 LoVo HB2
Figure 3 Dichloroacetate induced G2 phase arrest in colorectal cancer
cells with no effect on cell-cycle profiles of non-cancerous cells; 293 and
HB2. Cells were treated with 50mM DCA or vehicle control for 24h (A)
and 48h (B), stained with PI, and analysed with flow cytometry. For
analyses of statistical significances, we compared mean proportion of cells in
each phase of cell cycle (G1, S, and G2) in DCA-treated cells to mean
proportion of cells in the respective phases in untreated cells (* – significant
































HB2 LoVo SW480 HT29 293
Figure 4 Dichloroacetate reduced lactate levels in growth media in a
dose-dependent manner in both cancer and non-cancerous cells. Cells
were treated with range of doses of DCA for 48h, and extracellular lactate
levels were measured in the growth media using an auto-analyser. Results
are expressed as relative of control.
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sDCA treatment leads to dephosphorylation of the PDHE1a
sub-unit
DCA is thought to inhibit all four isoenzymes of PDK, and hence
reduce phosphorylation of the PDHE1a sub-unit, leading to, in
turn, activation of the PDH complex. To verify if the dephos-
phorylation of PDHE1a was occurring with DCA treatment in
the cell lines used, we used western blot analyses on lysates of
DCA-treated and untreated cells. In all cell lines, treatment
with 20mM DCA for 8h caused a dramatic reduction in signal
for phosphorylation at the pSer
293 site, but no change was detected
in the levels of total PDHE1a (Figure 6). Phospho-specific
antibodies for the other two phosphorylation sites, Ser
232 and
Ser
300, are not yet commercially available.
DISCUSSION
Differential effects of DCA on growth of cancer and
non-cancerous cells
We have shown that DCA induces a dose-dependent reduction
in growth of in vitro cultures of colorectal cancer cells and
non-cancerous cells. However, the cancer cells were more sensitive
to DCA, with a dose of 20mM causing a significant inhibition of
cancer cell growth, but having little effect on the non-cancerous
cells. We have shown that the components of this differential effect
are the following: a potent induction of apoptosis and cell-cycle
arrest in cancer cells, but not in the non-cancerous cells.
These conclusions support a simple model of differential
sensitivity to DCA. However, some data require further discussion.
First, 50mM DCA reduced growth of cultures of the non-cancerous
293 and HB2 cells, yet no increase in apoptotic cells or change in
cell-cycle profile of these cells was observed. A possible explana-
tion for these findings could be that this dose of DCA led to a
slower transit of these non-cancerous cells through all stages of the
cell cycle, without changing the relative proportions within each
stage. Second, our results indicate that DCA induced G2 arrest in
colorectal cancer cells. This is in contrast to previous studies,
which have shown G1 arrest or no change on cell-cycle profile with
DCA treatment (Cao et al, 2008; Wong et al, 2008). Wong et al
(2008) showed increased expression of PUMA in all the
endometrial cancer cell lines that had an apoptotic response to
DCA, and concluded that this p53 activation led to G1 arrest.
However, colorectal cancer cells in our study arrested in G2 phase
on treatment with DCA, and we did not find any induction of p53
by DCA in our colorectal cancer cell lines (data not shown).
Intriguingly, Cao et al (2008) found that the combination of DCA
and radiotherapy arrested prostate cancer cells in G2 phase,
although DCA on its own did not affect cell-cycle profile. Third, in
SW480 and LoVo cells, DCA treatment resulted in an increase in
the proportion of cells considered to be in the S phase. This
suggests an increase in proliferation as well as induction of
apoptosis. A similar finding was reported by Wong et al (2008) in
one of several endometrial cancer cells tested. An alternative
explanation is that a proportion of the cells observed to be in
‘S phase’ after DCA treatment of the cancer cell lines actually
represent apoptotic cells in the ‘sub-G2’ region, as has been
reported previously in lymphoma cells (Klucar and Al-Rubeai,
1997).
Changes in cellular metabolism with DCA treatment
DCA appeared to suppress lactic acid production from pyruvate in
both cancer and non-cancerous cells. In addition, treatment with
DCA led to dephosphorylation of PDHE1a, and hence activation of
PDH in all the cell lines investigated. Hence, the basis of DCA’s
differential effect on cancer and non-cancerous cells may reside in
its influence on mitochondrial function. Treatment with DCA
reduced the high DCm of all cancer cells but not of the non-
cancerous cells. This suggests that DCA, by inhibiting PDK and
hence activating PDH, promotes mitochondrial respiration that
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LoVo SW480 293
Figure 6 Dichloroacetate treatment reduced phosphorylation of
PDHE1a at pSer
293 site with no effect on the levels of total PDHE1a in
all the cell lines investigated. Whole-cell lysates were prepared after treating



















































































HB2 LoVo SW480 HT29 293
HB2 LoVo SW480 HT29 293
Figure 5 Dichloroacetate treatment reduced the intrinsic mitochondrial
membrane potential (DCm) in all cancer cells, increased DCmi n
non-cancerous 293 cells, and had no effect on DCm in non-cancerous
HB2 cells. Cells were treated with doses of DCA for 24h (A) and 48h (B),
stained with TMRM, and fluorescence was measured at 530/620nm at
371C (* – significant difference relative to control).
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sand induces apoptosis by the proximal mitochondrial pathway as
described in the previous studies (Bonnet et al, 2007; Cao et al,
2008; Wong et al, 2008). Induction of apoptosis and changes in
mitochondrial function were most pronounced in the highly
invasive and metastatic LoVo cells than the less invasive HT29
and SW480 cells. This could have clinical implications for the
treatment of metastatic colorectal cancer, as it is usually the
highly invasive metastatic cancers that are most resistant to
conventional chemotherapy, and which may be most sensitive to
PDK inhibition. In support of this, a recent study reported that the
colorectal tumours resistant to 5-fluorouracil are more likely to
have upregulated glycolysis, and hence more amenable to therapy
targeting cancer metabolism (Shin et al, 2009). In this regard, our
results contrast the findings of Wong et al (2008), who found
highly invasive endometrial cancer cells to be most resistant to
DCA treatment.
PDK inhibition as cancer therapy against colorectal cancer
We found doses of 20–50mM DCA gave differential responses
between cancer and non-cancerous cells. Thus, potential thera-
peutic DCA doses would be between 20 and 50mM. In addition, a
recent study reported that the IC50 of DCA for breast cancer cells
to be between 20 and 30mM (Ko and Allalunis-Turner, 2009). This
is in contrast to previous studies that have reported DCA to reduce
proliferation and induce apoptosis in cancer cells with doses as
low as 0.5–10mM (Bonnet et al, 2007; Wong et al, 2008; Sun et al,
2009). Dichloroacetate has been found to be relatively safe in
humans when used for treatment of lactic acidosis (Stacpoole
et al, 2003). The main side effects with up to 100mgkg
 1 DCA
are on the nervous system and the liver, causing mild sedation or
drowsiness, reversible peripheral neuropathy, and mild asympto-
matic elevation of serum transaminases reflecting hepatocellular
damage (Stacpoole et al, 1998). In addition, recent studies reported
that DCA effectively reduced tumour growth in clinically achiev-
able doses both in vitro and in vivo (Bonnet et al, 2007; Sun et al,
2009). It was suggested that DCA could rapidly translate to early-
phase cancer clinical trials (Michelakis et al, 2008). However, the
dose of DCA required to inhibit growth of colorectal cancer cells in
our study is unlikely to be achieved clinically without causing
significant side effects. The dose of DCA required to achieve the
equivalent plasma concentrations in vivo would be about five to
ten times than that used in clinical trials against lactic acidosis. It
appears that the colorectal cancer cells used in our study are more
resistant to DCA than lung, endometrial, and breast cancer cells.
Intriguingly, Sun et al (2009) in their study on breast cancer cells
found that DCA inhibited proliferation of cancer cells, but did not
induce apoptosis or cell death. These results were markedly
different to the effects of DCA observed on lung (Bonnet et al,
2007), endometrial (Wong et al, 2008), and colorectal cancer
cells in our study. Thus, although DCA inhibits growth of a variety
of cancer cells, the effect and the underlying mechanisms
seem to be cell-type dependent. A likely explanation for these
differential effects could be the difference in expression of the
PDK isoenzymes in the cancer cells examined. Dichloroacetate
is a non-specific inhibitor of PDK (Whitehouse and Randle, 1973),
and has a different Ki for each of the four PDK isoenzymes
(Bowker-Kinley et al, 1998). In addition, the four PDK isoenzymes
are known to be differentially expressed in various tissues. Thus,
there is a need to develop inhibitors to the individual PDK
isoenzymes that should allow cancer cell-type-specific metabolic
manipulation.
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